Iovance Biotherapeutics to Present at Wells Fargo Healthcare Conference and H.C. Wainwright Global Investment Conference

Iovance Biotherapeutics announced that senior leadership will present at the 2025 Wells Fargo Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference. The presentations will be webcast live and archived on the company's website. Iovance is focused on developing TIL therapies for cancer patients.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer patients, has announced its participation in two upcoming investor conferences. The company will be presenting at the 2025 Wells Fargo Healthcare Conference on September 5, 2025, at 8:00 a.m. ET in Boston, MA, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 11:00 a.m. ET in New York, NY. Investors can access both live and archived webcasts of these presentations through the company's investor relations website [1].

Iovance Biotherapeutics is focused on innovating, developing, and delivering novel polyclonal TIL therapies for patients with cancer. The company's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. Iovance is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to extend and improve life for cancer patients [2].

The upcoming presentations will provide investors with an opportunity to gain insights into the company's progress in developing TIL therapies and its plans for future growth. Iovance's participation in these high-profile conferences underscores its commitment to transparency and engagement with the investment community.

References:
[1] https://www.stocktitan.net/news/IOVA/iovance-biotherapeutics-to-present-at-upcoming-v7ui9mtd90xw.html
[2] https://www.marketscreener.com/news/iovance-biotherapeutics-enters-amended-sale-agreement-with-jefferies-ce7c50dbdb8ff220